<DOC>
	<DOCNO>NCT00008229</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radioactive drug holmium Ho 166 DOTMP kill cancer cell without harm healthy cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness melphalan without holmium Ho 166 DOTMP follow peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Melphalan With Without Holmium Ho 166 DOTMP Followed Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy melphalan without holmium Ho 166 DOTMP follow autologous peripheral blood stem cell transplantation patient multiple myeloma . II . Compare response rate overall survival patient treat regimen . III . Compare hematologic recovery rate time granulocyte engraftment patient treat regimen . IV . Compare toxicity regimens patient population . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord beta 2 microglobulin ( B2M ) test initial diagnosis ( B2M great 4 mg/L v B2M great 4 mg/L v unknown B2M ) . Patients randomize one two treatment arm . Prior stratification randomization , patient receive diagnostic dose holmium Ho 166 DOTMP within day -31 -10 . Patients adequate skeletal uptake diagnostic dose randomize therapy . Arm I : Patients receive holmium Ho 166 DOTMP IV 10 minute within day -10 -7 ( least 1 week 3 week diagnostic dose ) , melphalan IV 20-30 minute within day -3 -1 ( least 24 hour prior autologous peripheral blood stem cell ( PBSC ) transplantation ) , autologous PBSC transplantation day 0 . Arm II : Patients receive melphalan autologous PBSC transplantation arm I . Following transplantation , patient receive filgrastim ( G-CSF ) daily blood count recover . Patients follow 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 300 patient ( 150 per treatment arm ) accrue study within 9 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose multiple myeloma ( diagnosis within 12 month study ) schedule undergo autologous peripheral blood stem cell transplantation Prior diagnosis monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma ( SMM ) allow criterion diagnosis multiple myeloma meet within 12 month study Serum urinary Mprotein confirmation diagnosis ( IgA , IgD , IgG , IgE , light chain protein ) At least 10 % plasma cell bone marrow Must receive induction therapy without disease progression relapse initial response Prior induction therapy must complete 6 month stem cell collection 9 month transplantation Must undergone stem cell mobilization cyclophosphamide IV filgrastim ( GCSF ) The following diagnosis exclude : Nonsecretory multiple myeloma IgM myeloma Solitary bone extramedullary plasmacytoma Symptomatic MGUS SMM Symptomatic indolent multiple myeloma PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2 mg/dL SGPT great 2 time upper limit normal No clinical evidence amyloidosis involve liver Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 30 mL/min No clinical evidence amyloidosis involve kidney Cardiovascular : LVEF least 50 % No evidence amyloidosis echocardiogram No uncontrolled arrhythmia No symptomatic cardiac disease Pulmonary : FEV1 least 60 % OR FVC least 60 % OR DLCO least 60 % No symptomatic pulmonary disease No clinical evidence amyloidosis involve lung Other : HIV negative No cord compression No concurrent illness would preclude survival No clinical evidence amyloidosis involve autonomic nervous system gastrointestinal tract No known allergy vitamin C Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior thalidomide myeloma No prior peripheral blood stem cell bone marrow transplantation No concurrent thalidomide No concurrent interferon Chemotherapy : See Disease Characteristics No prior clarithromycin myeloma No 2 course prior induction therapy contain alkylating agent Endocrine therapy : No concurrent dexamethasone Radiotherapy : No prior radiotherapy 20 % bone marrow No great 30 Gy spinal cord Surgery : Not specify Other : At least 28 day since prior bisphosphonates No prior new experimental agent myeloma No concurrent experimental therapies No concurrent bisphosphonates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>